J&P Medi develops investment support project to revitalize stagnant industry < Medical devices/IT < Text of article

[의학신문·일간보사=김현기 기자] J&P Medi is taking the lead in revitalizing the stagnant industry by introducing a new business that combines its medical business solutions and networking capabilities.

J&P Medi (CEO Jeong Jeong-ho), a medical data platform company, announced on the 24th that it is launching an ‘innovative biotech and medical device company investment support project’ to supply new growth engines to the domestic pharmaceutical and bio markets.

According to J&P Medi, the ‘Innovative Biotech and Medical Device Company Investment Support Project’ is a business model that matches pharmaceutical and medical device companies with investment companies based on Maven Clinical Cloud solution capabilities and investment network, and makes large-scale investments through direct investment. It serves as a starting point for connection with the company.

In addition, we provide biotechs with end-to-end solutions ranging from funding opportunities and clinical trials to commercialization and licensing agreements, and provide investment companies with transparent support for business progress, including clinical trial progress of connected companies.

Currently, J&P Medi is known to have a vast network of global investment companies, including Pavilion Capital of Singapore’s sovereign wealth fund Temasek, Murex Partners, Kakao Ventures, Aju IB Investment, and Gentium Partners, which are major institutional investors.

J&P Medi plans to focus on large-scale business expansion and diversification starting with this innovative biotech support project. The strategy is to expand Maven Clinical cloud-centered digital solution capabilities into more diverse areas.

Through this, we aim to become a comprehensive DX company in the life sciences field that supports efficient work not only in clinical trials but also in all processes from the initial planning stage of pharmaceutical and medical device business to actual commercialization.

CEO Jeong Jeong-ho said, “Creating a structure where various stakeholders can co-exist inevitably starts with empathizing with the concerns of the customers who are creating the initiative,” and added, “The company is growing into a digital medical hub centered on technology. “We have come up with a new business to expand our platform capabilities and set a precedent for a virtuous cycle that contributes to the development and revitalization of the industry.”

He continued, “We will continue to increase the influence of our cloud service ecosystem and make every effort to expand our business through J&P Medi so that the entire process, from development of drugs and medical devices to follow-up management as well as digital-based clinical trials, can be carried out easily and quickly. “He emphasized.